Physician profile
Joshua Beer
NPI 1588736268
$1,501.06
in general payments reported to CMS, 2019-2025
14 companies · $300 in 2025
The $300 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $76.05 · 2020: $60.93 · 2021: $67.86 · 2022: $296 · 2023: $405 · 2024: $295 · 2025: $300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,000.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $738.06 | 2019-2025 | Cequa |
| Bausch & Lomb Americas INC. | $119.80 | 2022-2025 | Miebo, Xiidra |
| Oyster Point Pharma, INC. | $101.43 | 2022-2024 | Ryzumvi |
| Alcon Vision LLC | $83.96 | 2022-2025 | Tryptyr, Eysuvis |
| Tarsus Pharmaceuticals, INC. | $82.29 | 2024-2025 | Xdemvy |
| Allergan, INC. | $81.57 | 2020-2022 | |
| Johnson & Johnson Vision Care, INC. | $78.63 | 2022-2023 | Acuvue |
| Novartis Pharmaceuticals Corporation | $56.45 | 2023 | |
| Dompe US, INC. | $49.52 | 2023-2025 | Oxervate |
| Abbvie INC. | $29.30 | 2022 | |
| Eyevance Pharmaceuticals LLC | $23.92 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $23.92 | 2023 | Zilretta, Iovera, Exparel |
| Harrow Eye, LLC | $20.88 | 2024 | Vevye |
| Kala Pharmaceuticals, INC. | $11.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Beer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.